



ASX Announcement


26 March 2020

Creso successfully delivers its first shipment of cannaQIX® to South Africa for launch in Q2

Highlights

- Creso Pharma has successfully completed all the export /importing procedures and delivered its first shipment of cannaQIX® regular to Pharma Dynamics in South Africa
- Pharma Dynamics, a subsidiary of Lupin Limited (NSE:LUPIN), is a leading pharmaceutical company in South Africa and ranks as the fifth biggest generic player in the country.
- Pharma Dynamics is planning to launch the Company's cannaQIX® regular product under the brand name "Cannamics" in Q2 in South Africa

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to announce that the first order of its cannaQIX® regular product was successfully delivered to the South African pharmaceutical company, Pharma Dynamics, who plan to launch it in South Africa under the brand name "Cannamics" (shown below) in Q2.



Pharma Dynamics is a leading pharmaceutical company in South Africa, a subsidiary of Lupin Limited (NSE:LUPIN), and is ranked the fifth biggest generic pharmaceutical company in SA. Pharma Dynamics leads with high quality generics at affordable prices and is well known for its investments into innovative wellness programs towards holistic healthcare. Its growing range of over-the-counter products include cold and flu, allergy, heartburn and immune booster products. Their products are consistently prescribed and recommended by leading doctors and pharmacists countrywide.

**cannaQIX® regular**

The cannaQIX® range of products are cannabidiol (CBD) hemp oil-based nutraceuticals using Creso Pharma's proprietary innovative delivery technology. They contain broad spectrum organic hemp oil extract with CBD aiming to reduce stress and to support mental and nervous functions.

cannaQIX® regular is sugar-free and contains no tetrahydrocannabinol (THC). The standardized, user-friendly strength and formulation allows precise dosage control and the lozenges have a more palatable taste compared to oils.

The cannaQIX® range has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso Pharma's partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a "Swiss Made" label.

Dr. Miri Halperin Wernli, Co-Founder and CEO said: "We are very excited to have completed the first delivery of cannaQIX® regular to Pharma Dynamics in South Africa. We are delighted that customers in South Africa will be able to access our affordable, high-quality, hemp oil based GMP nutraceutical products from Q2 2020 onwards and we look forward to being able to broaden this distribution into additional countries through Africa.

Carole Abel, Director Commercial Operations said: " We are very happy that in spite of the current challenging circumstances, and thanks to a collaborative effort, we managed to deliver this first shipment on time. We would like to specifically thank our manufacturing partner Dr. med Aufdermaur AG (Domaco) for their continuous support, commitment and professionalism."

Ends**Authority and Contact Details**

This announcement has been authorised for release by Dr. Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

EverBlu Capital
E: info@everblucapital.com
P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network
E: julia@thecapitalnetwork.com.au
P: +61 419 815 386



About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

About Pharma Dynamics

Pharma Dynamics is the 11th largest pharmaceutical company in South Africa (SA) with a well-established footprint spanning across several African countries. As of 2012, it maintains its position as the biggest supplier of cardiovascular pharmaceuticals in SA, both in terms of value and volume. It boasts with a range of products across therapeutic areas including cardiovascular (CVS), central nervous system (CNS), gastrointestinal and men's health therapies. In 2013, it entered the SA anti-infective market, supplying IV antibiotics to hospitals. The firm's over-the-counter (OTC) product portfolio is also growing and includes antihistamines and allergy treatments, cold & flu medication and heartburn treatment, among others. Pharma Dynamics is wholly owned by Lupin Laboratories, the fourth largest generic pharmaceutical company globally by market capitalisation.

About Domaco, Dr. med Aufdermaur AG

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimise their absorption.

To learn more please visit: www.domaco-pharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.



The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.